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Abstract 
The eye is continuously exposed to solar UV radiation and pollutants, making it prone to 
oxidative attacks. In fact, oxidative damage is a major cause of age-related ocular diseases 
including cataract, glaucoma, age-related macular degeneration and diabetic retinopathy. 
Since the nature of lens cells, trabecular meshwork cells, retinal ganglion cells, retinal 
pigment epithelial cells and photoreceptors is post-mitotic, autophagy plays a critical role in 
their cellular homeostasis. In age-related ocular diseases, this process is impaired, thus, 
oxidative damage becomes irreversible. Other conditions such as low- grade chronic 
inflammation and angiogenesis also contribute to the development of retinal diseases 
(glaucoma, age-related macular degeneration and diabetic retinopathy). As melatonin is 
known to have remarkable qualities such as antioxidant/antinitridergic, mitochondrial 
protector, autophagy modulator, anti-inflammatory and anti-angiogenic, it can represent a 
powerful tool to counteract all these diseases. The present review analyzes the role and 
therapeutic potential of melatonin in age-related ocular diseases, focusing on nitro-oxidative 
stress, autophagy, inflammation and angiogenesis mechanisms. 
 
KEYWORDS: Melatonin; Aging; Aged-related ocular diseases; Cataract; Glaucoma, Age-
related macular degeneration; Diabetic retinopathy. 
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1. INTRODUCTION 
Aging involves a progressive deterioration of the body´s regulatory systems -immune, 
endocrine and nervous system- leading to loss of homeostasis. 1 The oxidative and 
inflammatory stress play a fundamental role in this decline. With age, the metabolic 
production of free radicals such as reactive oxygen species (ROS) as well as reactive 
nitrogen species (RNS) exceeds the level of antioxidant enzymes. Therefore, ROS oxidise 
membrane lipids, DNA and proteins in the cellular senescence process.2 Since ROS are 
principally produced by the respiratory chain, mitochondria are the major sites of oxidation. 
This oxidative injury damages mitochondrial macromolecules, mainly DNA, that impairs 
mitochondrial function and generates more ROS.3 ROS, (mainly mitochondrial hydrogen 
peroxide as well as superoxide anion), induce the autophagy process to reduce oxidative 
damage.4,5 This process eliminates non-functional proteins as well as damaged organelles 
through their sequestration within an autophagosome and posterior degradation via 
lysosomes. Consequently, oxidatively-damaged mitochondria are degraded by a specialized 
form of autophagy called mitophagy. Nevertheless, during aging, mitophagy (mitochondria 
degradation) and biogenesis (mitochondria synthesis) are diminishing as well.6-9 
Consequently, defective mitochondria gradually replace healthy organelles which finally 
leads to the death of senescence cells due to a lack of ATP.3  
Furthermore, ROS can promote telomere erosion contributing to cellular aging and thus to 
the development of age-related diseases.10-13 Indeed, Salpea and colleagues have shown a 
link between mitochondrial production of ROS and telomere attrition in type 2 diabetes.12 
Another condition that contributes to senescence progression is inflammation. During aging, 
pro-inflammatory compounds (e.g. coagulation factors and cytokines such as interleukin 6, 
IL-6) surpass anti-inflammatory compounds (e.g. transforming growth factor beta and 
cytokines such as IL-10) resulting in a chronic low-grade of inflammation.14 Senescence cells 
secrete pro-inflammatory factors which attract and activate immune cells, the so-called 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
senescence-associated secretory phenotype (SASP). Immune cells produce new 
inflammatory compounds but also ROS/RNS that destroy senescent and/or abnormal cells 
as well as pathogens.1 Moreover, oxidized mitochondrial DNA and mitochondrial cardiolipin 
activate NLRP3 inflammasome (a high molecular weight protein complex) that promotes the 
maturation of pro-inflammatory cytokines such as IL-1β and IL-18.15 These cytokines bind to 
cell surface receptors triggering intracellular signal cascades, which finally activate 
transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB).1,15 This protein regulates the expression of genes encoding to pro-inflammatory 
cytokines and pro-oxidant proteins.16-18 Consequently, NF-κB amplifies and prolongs 
inflammatory as well as oxidative response. On the other hand, ROS/RNS can also interact 
with NF-κB signaling pathway at different levels. For a more detailed review of ROS and NF-
κB crosstalk see reference.18 
 
2. MELATONIN AND HUMAN AGING 
2.1 Circadian rhythms and melatonin signaling  
Melatonin is an indole-derived hormone secreted mainly by the pineal gland allowing the 
entrainment of the circadian and seasonal rhythms. Its production is also regulated by 
light/dark cycle via the suprachiasmatic nucleus, the master clock that generates 24 hour 
rhythms in mammals.19,20 Therefore, melatonin concentrations display a circadian rhythm 
with low values during the daytime and high values at night.21 Nocturnal levels of melatonin 
tend to decrease with age.22,23 This fact can be explained by the deterioration of aged 
suprachiasmatic nucleus.24,25 In addition, patients with age-related diseases such as 
Alzheimer and type 2 diabetes produce lesser melatonin than age-matched controls.26,27  
Since many physiological processes display circadian rhythmicity, the reduction of melatonin 
levels might cause an internal desynchronization, altering body homeostasis.28 
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Melatonin effects are principally associated to its capacity to activate specific membrane 
receptors termed MT1, MT2 and the putative MT3.29-31 MT1 and MT2 receptors are members of 
the G protein-coupled hepta-helical receptor (GPCR) family. These receptors can couple to 
Gαi (pertussis toxin-sensitive), Gαq (pertussis toxin-insensitive) and Gβγ proteins. 
Consequently, activation of MT1/MT2 receptors triggers different signal cascades (Fig. 1). 
Classically, melatonin inhibits adenylate cyclase but can also activate phospholipase C or 
inhibit guanylate cyclase.32 Furthermore, melatonin can activate the extracellular signal-
regulated kinase/mitogen-activated protein kinase (ERK/MAPK) and the phosphatidylinositol 
3-kinase/protein kinase B (PI3K/Akt) pathways, as well as being able to regulate channels 
(e.g. inward rectifier potassium channels, Kir3.1/2).32,33 In fact, several authors have 
suggested that the ERK/MAPK pathway, represents a major component of melatonin 
signaling during oxidative stress.34-36 For a more detailed review of melatonin signaling 
see.32,33  
 
Additionally, melatonin and its metabolites (e.g. N1-acetyl-N2-formyl-5-methoxykynuramine, 
AFMK, and N1-acetyl-5-methoxykynuramine, AMK) possess added anti-aging effects 
including antioxidant, protection of mitochondria function as well as anti-inflammatory.37-41 
 
2.2 Melatonin and the nitro-oxidative stress 
Antioxidant and antinitridergic effects of the indole-derived melatonin and its metabolites are 
mainly mediated by its ability to scavenge free radicals but also through specific signaling 
(see above) and transcription of stress-related genes (Table 1).32,37-44 Therefore, melatonin 
regulates the expression of genes encoding to antioxidant enzymes and to neuronal nitric 
oxide synthase (nNOS, isoform constitutively expressed) as well as inducible nitric oxide 
synthase (iNOS, isoform expressed during inflammatory processes).45-52 These genomic 
actions are mediated by redox-sensitive transcription factors such as nuclear factor erythroid 
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2‐related factor 2 (Nrf2) and NF-κB. Melatonin activates Nrf2 factor under nitro-oxidative 
stress (stress induced by ROS and RNS) and thereby increases the expression of 
antioxidant enzymes (see Figure 1).47,48 Likewise, melatonin blocks NF-κB activity inhibiting 
the expression of pro-inflammatory genes such as NOS and cyclooxygenase-2 (COX-2) 
enzyme (Fig. 1).47,48 For a specific review of genomics actions of melatonin see.53  
Regarding the antinitridergic effects of melatonin, it is noteworthy that its metabolite AMK 
also inhibits nNOS and cytosolic as well as mitochondrial (i-mtNOS) iNOS (Table 1).39,41 
These enzymes catalyze the synthesis of nitric oxide (NO) a signaling molecule that 
participates in several cellular processes and is the source of RNS. In mitochondria, 
cytosolic/mitochondrial NO regulates the respiratory chain, the generation of free radicals 
and the mitochondrial apoptosis (Table 1).54,55  
Besides this, melatonin improves mitochondrial electron flux, stimulates de novo synthesis of 
respirasomal subunits, prevents Ca2+ overload in mitochondrial matrix, exerts antioxidant 
activity (e.g. to avoid cardiolipin peroxidation) (actions reviewed in38,42,56,57) and promotes 
mitochondrial biogenesis.56-59 Again, AFMK and AMK metabolites contribute to the 
mitochondrial protection effect of melatonin.41,60,61 
With regards to mitophagy (selective autophagy of mitochondria), melatonin can act as either 
pro- or anti- autophagy depending on cellular necessities and oxidative stress level.62 
Therefore, Guo and colleagues reported the pro-autophagy (and thus cytoprotective) effect 
of melatonin in ischemia/reperfusion-injured N2a cells.63 Conversely, Teng and colleagues 
demonstrated the anti-autophagy (and thus neuroprotective) role of melatonin in neuronal 
cells of rats treated with arsenite.59 The potential role of melatonin in the regulation of 
autophagy/mitophagy during aging remains unknowns. Only, Caballero and coworkers 
observed that autophagic processes of aged animals were unaltered by melatonin 
treatment.64  
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2.3 Melatonin and inflammation 
Melatonin can also prevent the onset (due to its effects as antioxidant, antinitridergic, 
mitochondrial protector, COX-2 inhibitor and anti-excitatory) and progression (due to its 
effects as direct and indirect immune modulator) of inflammation. Therefore, Melatonin and 
its metabolites can specifically prevent the gene expression and activation of COX-2, which 
regulates prostaglandins production and so are a key factor in the initiation of inflammatory 
process (Table 1).40,47,48 Additionally, this indole-derived compound has anti-excitatory 
properties, which also allows it to prevent neuroinflammation. Indeed, a possible cause of 
neuroinflammation is the excitotoxicity, a process of neuronal death originated by 
accumulation of neurotransmitter glutamate around the synaptic cleft. Excessive glutamate 
concentration increases NOS expression, principally nNOS, which produces high levels of 
NO.54,65 Finally, NO may induce apoptosis through DNA damage and mitochondrial 
respiration impairment.54,65 Since melatonin and its metabolites inhibit the expression of 
nNOS and iNOS, these compounds have anti-excitatory effects (Table 1).39,41,46,49,51 
Furthermore, melatonin can modulate GABA, glutamate and glycine receptors thus acting as 
a direct anti-excitatory molecule (Table 1).66-73 
 
Not only do melatonin and its metabolites reduce the level of NO that produces immune-
modulatory effects (effects summarized in74) but they also reduces iNOS expression through 
the inhibition of NF-κB pathway (Table 1).46,53 As we previously commented, this pathway is 
essential to amplify inflammatory process and thus, melatonin might also act as an anti-
inflammatory compound.16,38,42 Furthermore, melatonin is an immune modulator per se and 
controls the release of various anti-inflammatory and also pro-inflammatory cytokines.38,42,75 
This action is mediated by pineal and extra pineal melatonin (melatonin synthetized by 
immune cells) via membrane receptors (mainly MT1 receptors) as well as nuclear receptors 
of RZR/ROR family present in immune cells (Fig. 1).76-78 In this context, several authors have 
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reported that melatonin can act as an anti-inflammatory agent in chronic low-grade 
inflammation typical of aging.38,42,79 By contrast, and as Carrillo-Vico and colleagues 
describe, under basal or immunosuppressive conditions melatonin promotes inflammation.80  
 
2.4 Melatonin and its effect on insulin and sirtuins actions 
The beneficial effects of melatonin, are not only limited to the aforementioned paths. The 
connection between melatonin and insulin/insulin-like growth factor 1 (IGF-1) as well as 
sirtuins signaling pathways provides additional anti-aging effects.81 Insulin/IGF-1 pathway 
regulates mitochondrial activity and energy metabolism, therefore it is involved in neuronal 
survival.82-84 In fact, activation of this pathway improves mitochondrial function in 
lymphoblasts from patients with Huntington's disease.85 Melatonin modulates insulin/IGF-1 
receptor phosphorylation and regulates PI3K/AKT as well as ERK/MAPK pathways in 
isolated rat pancreatic islets (Fig. 1).86 Indeed, this indole-derived compound improves 
pancreatic functioning of senescence accelerated mouse (SAMP8) and counteracts insulin-
resistance characteristic of metabolic syndrome as well as diabetes type 2.87-89 
Additionally, melatonin can indirectly regulate the autophagy process via PI3K/AKT 
modulation (Table 1). This critical enzyme of insulin/IGF-1 pathway activates the mammalian 
target of rapamycin (mTOR) signaling and thus suppresses autophagy.90 
Sirtuins are a family of NAD+- dependent histone deacetylases.91,92 These enzymes, 
deacetylate histone and non-histone substrates such as Forkhead box O (FoxO) 
transcription factors93,94 and NF-κB,95 thereby sirtuins participate in several functions related 
with aging including energy metabolism, stress resistance, cell survival and circadian 
rhythms.96 Sirtuin subtype 1 (SIRT1) regulates the expression of IGF-1 and its receptor97 as 
well as the FoxO transcription factor which is a downstream target of insulin/IGF-1 
pathway.93,94,98 Furthermore, it protects pancreatic beta cells by inhibition of NF-κB,99 
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modulates insulin secretion100 and ameliorates insulin sensitivity, principally under insulin-
resistant conditions such as in diabetes.101  
In response to oxidative stress, SIRT1 reduces apoptosis induced by FoxO subtype 3 
(FoxO3) factor.93 Additionally, SIRT1 regulates the expression of antioxidant enzymes 
through a FoxO-dependent mechanism102-104 and through mitochondrial NOS enzymes.105 
Therefore, sirtuins are also involved in the control of free radical levels and mitochondrial 
biogenesis which are key factors in the aging process. Furthermore, sirtuin-mediated 
deacetylation is critical for autophagy regulation (Table 1). Indeed, SIRT1 promotes the 
expression of components of the autophagy process via deacetylation of transcription factors 
such as FoxO1 and FoxO3.81,106 
In relation to the ability to reduce ROS load, sirtuins also inhibit the pro- oxidant and pro- 
inflammatory factor NF-κB.95,107 In fact, Schug and colleagues suggest that modulators of 
sirtuins might be useful for the treatment of chronic inflammation and its associated 
diseases.108  
As previously mentioned, oxidative stress can promote telomere attrition.10-13 SIRT1 can 
reduce oxidative stress but also, maintains telomere stability (Table 1).109,110 
Finally, sirtuins link cellular metabolism to the circadian molecular clock machinery. SIRT1 
modulates circadian clock gene expression through its association to CLOCK/BMAL1-
complex.111 Furthermore, SIRT3 regulates rhythmicity of mitochondrial activity (Table 1).112 
Melatonin can modulate SIRT1 expression and subsequently modify the levels of its 
acetylated substrates (Table 1).113-117 Gutierrez-Cuesta and colleagues have shown the 
ability of melatonin to upregulate SIRT1 in SAMP8 mice.114 In accordance with this result, 
melatonin induces SIRT1 expression in sleep-deprived rats113 and in neuronal cultures from 
aged rat cerebellum.117 Conversely, melatonin decreases SIRT1 expression under tumoral115 
and inflammatory conditions.116 In any case, this modulation may explain some of melatonin 
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anti-aging actions. In fact, Lim and colleagues have shown that some of the anti-
inflammatory properties of melatonin are dependent of SIRT1.116  
Another possible action of melatonin mediated by sirtuins is its influence on telomerase 
activity. Melatonin stimulates telomerase activity on normal cells118 and SIRT1 is necessary 
for telomere elongation.109,110 Conversely, and under tumoral conditions, melatonin inhibits 
the telomerase activity.119,120 
 
3. MELATONIN AND AGING-RELATED EYE DISEASES 
Melatonin as a regulator of physiological circadian rhythm processes, as an antioxidant, an 
anti-inflammatory agent and as a protector of mitochondria function, could represent a 
powerful tool to counteract age-related conditions including diseases of the eye. This indole-
derived compound is also synthesized in human ocular tissues such as ciliary body and 
retina, which present specific melatonin receptors and therefore it might control the 
physiology of these ocular targets.121 Additionally, melatonin and melanopsin (a regulator of 
ocular melatonin synthesis) are also produced in the human lens, although melatonin 
receptors have only been discovered in fiber cells of frog lens.121-123  
Since the eye is continuously exposed to solar UV radiation and pollutants, this organ is 
prone to oxidative attacks. In fact, oxidative stress is involved in the development of many 
ocular diseases including cataract, glaucoma, age-related macular degeneration and diabetic 
retinopathy.124 All these pathologies are associated with age and consequently, they may be 
the result of an imbalance between ocular ROS generation and the expression of antioxidant 
enzymes (see introduction section about cellular senescence process and reference124). In 
this context, mitochondria are essential in the onset and progression of age-related ocular 
diseases.125-127 Ocular mitochondria are the source of antioxidant and protein repair systems 
but are also the main endogenous source of ROS.127 Consequently, oxidatively-damaged 
mitochondria are unable to maintain redox balance and to repair damaged proteins.127 
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Furthermore, ROS produced by injured mitochondria induce autophagy/mitophagy 
process.5,128 In the eye, autophagy plays a critical role in maintaining normal cellular 
function.129 Indeed, alterations in the autophagy process contribute to the development of 
age-related ocular diseases.129 
 
All these oxidative stress-derived events play a particularly critical role in the onset as well as 
the progression of age-related retinal pathologies including glaucoma, age-related macular 
degeneration and diabetic retinopathy. Indeed, the retina is especially vulnerable to ROS 
damage due to its constant exposure to visible light that causes photooxidation, its 
extraordinary concentration of polyunsaturated fatty acids (mainly docosahexanoic acid, 
DHA), which are especially sensible to peroxidation, and its high metabolic activity. 
Additionally, oxidative stress triggers retinal para-inflammation process.130 This process tries 
to restore retina functionality during aging but if it fails and becomes chronic (low-grade 
inflammation) it can then contribute to the development of age-related retinal diseases.130  
 
3.1. Cataracts 
According to a 2012 World Health Organization (WHO) report, cataracts are responsible for 
33 per cent of visual impairment and 51 per cent of blindness worldwide.131 Cataracts are 
commonly associated with age. As the lens ages, fiber cells accumulate high protein 
concentration forming aggregates. These aggregates scatter light and impede its focus on 
the retina.132 Aged lens cells also present high ROS concentration that contributes to the loss 
of transparency.132 Glutathione and mitochondria antioxidant enzymes control redox balance 
in the lens. During aging process, glutathione levels decline and mitochondria are damaged. 
Therefore, cellular redox balance is broken down and protein repair systems fail.127,133 
Concurrently, autophagy and mitophagy processes attempt to restore lens homeostasis but 
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their failure can often result in more ROS, oxidation and finally in cataract formation.134 
Indeed, deletion of autophagy-related genes causes cataracts.135 
In addition to age, other factors such as light exposure can also contribute to the oxidative 
stress-induced mitochondrial damage.136 
 
3.1.1 The therapeutic potential of melatonin in cataracts 
Melatonin, as a direct and indirect antioxidant, reduces cataract formation in rats (Fig 2).137-
142
 This neurohormone reduces the level of lipid peroxidation, enhances the production of 
glutathione and increases the activity of antioxidant enzymes in rats with cataracts.137,139,143 
In human lens epithelial cells (HLECs), melatonin inhibits H2O2-induced intracellular ROS 
generation and cell death through the activation of the PI3K/Akt signaling pathway (Fig. 1 
and 2).144 Bai and colleagues have suggested the possible therapeutic role of melatonin to 
prevent age-related cataracts by these receptor-mediated effects.144 More recently, 
Babizhayev and Yegorov claimed a new approach for treating cataracts based on 
mitochondria-targeted antioxidants.125 Consequently, and due to its antioxidant and 
mitochondria effects, melatonin seems to be a promising candidate in cataract management.  
PI3K/Akt cascade can also be transactivated secondarily to MAPK pathway activation.32 
Indeed, MAPK pathway is a key component of melatonin signaling during oxidative stress 
(Fig. 1).32 Moreover, MAPK signaling also plays a critical role in lens homeostasis.145 In fact, 
Shakespeare and colleagues have demonstrated that the constitutive activation of MAPK 
pathway increases connexin 50 - gap junction protein which mediates intercellular 
communication - activity producing cataract.145  
Regarding connexins, several authors have demonstrated its importance in cataract 
development.145,146 Accumulation of ROS in age lenses alters gap junction function, probably, 
by oxidative degradation of connexins.146,147 Wild-type and mutant connexins such as 
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CX50P88S – a connexin associated with cataracts – are degraded by autophagy.148 
Therefore, autophagy might contribute to these functional alterations of gap junction 
proteins.148 
Melatonin can also regulate connexin expression as well as autophagy process under 
oxidative stress, and may thereby control intercellular communication mediated by gap 
junctions (Fig 2).62,149,150  
 
As mentioned before, ROS can also promote telomere erosion, which contributes to cellular 
aging process.10-13 In this context, Huang and colleagues have demonstrated that the 
oxidative stressor H2O2 increases the rate of telomere shortening in HLECs cells.151 Since 
aged lenses accumulate ROS, telomere length of lens epithelial cells can be a marker of 
aging and cataractogenesis.152 Again, melatonin as a powerful antioxidant and inducer of 
telomerase activity as well as of sirtuins (these last actions under normal conditions) may 
prevent telomere attrition (Fig 2).42,113,114,117,118 Regarding sirtuins, Li and colleagues 
demonstrated that SIRT1 mRNA level decreases with age and the grade of human age-
related cataract.153 Indeed, a stabilizer of SIRT1-substrate interaction such as resveratrol,154 
prevents cataract formation in rats.155 Conversely, Zheng and Lu observed a higher level of 
SIRT1 mRNA and protein in lens of cataract patients than in normal lens.156 
 
3.2. Glaucoma 
Glaucoma is the second most common cause of visual impairment (2% of global cases) and 
blindness (8% of global cases) worldwide.131 It agglutinates a group of eye diseases 
characterized by progressive loss of retinal ganglion cells and subsequent damage to the 
optic nerve that eventually results in blindness.157 The most prevalent type of glaucoma is the 
primary open-angle glaucoma whose prevalence increases exponentially with age.158 
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Additionally, Tezel and colleagues have suggested that an accelerated aging process 
accompanies glaucomatous neurodegeneration.159 Indeed, the tissues involved in glaucoma 
- retina and trabecular meshwork (TM) - experiment remarkable changes during aging 
process.160-165 Consequently, retinal ganglion cells (RGC) of aged mice are more vulnerable 
to injury than cells of young animals.165 Regarding TM, their numbers of cells decrease with 
age and especially in glaucoma condition.160,162 Furthermore, De la Paz and Epstein have 
reported an age-dependent decline of superoxide dismutase activity in trabecular tissue.161 
Since glaucoma is an age-related disease, nitro-oxidative stress and particularly 
mitochondrial stress are also essential in its onset and progression. In fact, some authors 
have demonstrated the existence of a high level of stress proteins and their antibodies in the 
eyes and serum, respectively, of glaucomatous patients.166,167 Furthermore, elevated levels 
of iNOS activity have also been detected in astrocytes of the optic nerve head, endothelial 
cells of iris capillaries, aqueous humor and TM of glaucoma patients.168-171  
Mitochondria of several ocular cells including TM cells and retinal ganglion cells present 
molecular and functional changes during glaucoma (reviewed in172). Glaucomatous TM cells 
present a defect in mitochondrial complex I and a higher mitochondrial permeability than 
normal cells.173,174 This prompts the generation of more ROS, mitochondrial membrane 
depolarization as well as impairing intracellular calcium homeostasis.173,174 Consequently, 
glaucomatous TM cells are especially vulnerable to calcium stress and thus to cell death.173 
Several authors have demonstrated that the apoptosis of retinal ganglion cells is also due, at 
least in part, to a decrease in their mitochondrial membrane potential and an increase in their 
membrane permeability.175,176 Furthermore, Wang and colleagues have suggested that in the 
early stages of glaucoma occurs a non-apoptotic cell death (called paraptosis), which is also 
triggered by mitochondrial damage.177In addition to age, other factors such as light exposure, 
high intraocular pressure (IOP) and hypoxia can also contribute to the oxidative stress-
induced mitochondrial damage.178,179  
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Regarding light exposure, some authors have demonstrated that visible light stimulates the 
production of mitochondrial ROS and induces intrinsic apoptotic pathway, which is 
associated with mitochondrial events, in retinal ganglion cells.180,181 Since this detrimental 
effect is more marked when cells are energetically comprised, the authors suggest that light 
acts as an additional source of stress for ganglion cells already submitted to mitochondrial 
damage by other factors such as age and high IOP.180,181 
High IOP has classically been considered the most important cause of glaucomatous 
damage and currently, it is the only modifiable factor.157,182 Elevation of IOP can occur due to 
an imbalance between aqueous humor secretion across the ciliary epithelium and its 
drainage, which is decreased with age and glaucoma, through TM.183,184 Some authors have 
demonstrated that the elevation of IOP in animals (models of chronic pressure-induced 
glaucoma) results in a high level of retinal lipid peroxidation, protein nitration as well as 
protein oxidation and mitochondrial membrane depolarization of retinal ganglion cells.185-189 
Mitochondrial dysfunction has also been observed in cultured retinal ganglion cells submitted 
to elevated hydrostatic pressure.190 Furthermore, high IOP triggers retinal glutamate receptor 
(mainly N-methyl-D-aspartate, NMDA receptor but also α-amino-3-hydroxy-5-methyl-4-
isoxazoleproprionic acid, AMPA receptor) activation that permits the rapid influx of calcium 
ions impairing intracellular calcium homeostasis and at the same time increasing ROS/RNS 
generation.191-193 These effects also evoke mitochondrial dysfunction that finally leads to 
neuronal death by apoptosis and prompts calcium-dependent exocytosis of glutamate from 
injury neurons that induces further excitotoxic damage to adjacent neurons.194,195 
Additionally, mitochondrial dysfunction also increases the sensitivity of neurons to glutamate 
excitotoxicity and therefore leads to a lower concentration of glutamate, which is sufficient to 
induce neuronal death.196-198 
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On the other hand, elevation of IOP in animals results in a marked activation of microglial 
and macroglial cells.199-201 Activated glial cells contribute to age-related chronic low grade 
inflammation via the release of substances such as TNFα and NO that act as immune-
modulators and as cell death mediators.74,130,164,202-205 
Retinal hypoxia, which can be secondary to or independent of high IOP, is also implicated in 
the development of glaucoma.179,206,207 In fact, Kergoat and colleagues have demonstrated 
that retinal ganglion cells are particularly sensitive to systemic hypoxic stress.208 Hypoxia 
induces the expression of the hypoxia inducible factor -1α gene and its gene targets vascular 
endothelial growth factor (VEGF) and NOS that mediate inflammation, cell death and 
disruption of the blood retinal barrier.209 Additionally, hypoxic insult provokes glutamate 
release, which contributes to the retinal ganglion cells damage.207 
 
3.2.1 The therapeutic potential of melatonin in glaucoma 
Some authors have demonstrated that melatonin can counteract several etiopathogenic 
mechanisms for glaucomatous neurodegeneration, including elevation of IOP, nitro-oxidative 
stress, excitotoxicity and glial activation (Fig. 2). 
It is well known that the melatonergic system is involved in the circadian rhythms of IOP (Fig. 
2).210,211 Indeed, a dysfunction of melatonin signaling triggers elevation of nocturnal IOP and 
loss of retinal ganglion cells (Fig. 2).212 Additionally, exogenous melatonin and its analogues 
lower IOP in mammals, including humans (Fig. 2).213-221 This ocular hypotensive effect seems 
to be mediated by ciliary body receptors (MT2 and an unidentified receptor classically named 
MT3) and final inhibition of ciliary chloride secretion.29,31,222,223 Furthermore, melatonergic 
compounds provide a sustained reduction in IOP through regulation of ciliary genes 
expression and potentiate the hypotensive action of classic anti-glaucomatous drugs such as 
timolol and brimonidine.224-226  
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Belforte and colleagues have proved in a model of chronic pressure-induced glaucoma, that 
melatonin also increases retinal antioxidant defenses (e.g. it increases SOD activity and 
glutathione level) (Fig. 2).227 It also, reduces lipid peroxidation, NOS activity, the loss of 
retinal ganglion cells and the extracellular glutamate level (increasing glutamate uptake as 
well as glutamine synthetase activity and reducing glutaminase activity) (Fig. 2).227 These 
effects may be mediated, at least in part, by the transcription factor Nrf2, which plays a 
critical role in oxidative stress-induced retinal ganglion cell death (Fig. 2).228 In fact, Nrf2 
presents antioxidant as well as anti-inflammatory effects, improves mitochondrial function 
and stimulates autophagy.229 This transcription factor reduces the effects of many 
NO/ONOO- cycle elements (e.g. oxidative stress, iNOS induction, inflammatory cytokines, 
mitochondrial dysfunction, excitotoxicity and intracellular calcium) in glaucomatous retinal 
ganglion cells and TM cells.230 Regarding NO, several authors have demonstrated that NO 
plays an important role in IOP homeostasis (reviewed in231). Consequently, an inhibitor of 
NOS triggers TM contraction and reduces flow rates through TM.232-234 Moreover, Ellis and 
colleagues have suggested that reduction of NO may increase outflow resistance through its 
effect on Schlemm’s canal cells.235 Curiously, melatonin as a NOS inhibitor could act on TM 
iNOS and thereby, increase outflow resistance (Fig. 2). In this sense, Alkozi and colleagues 
have found that the AH of individuals with high IOP presents higher melatonin concentration 
than normotensive subjects.236 Consequently, melatonin could act on ciliary cells but also it 
could contract TM and finally, be unable to lower IOP. Nevertheless, Chiquet and colleagues 
have found comparable melatonin concentration in AH as well as in plasma of glaucomatous 
and healthy individuals.237 Since TM plays a critical role in glaucoma onset and progression, 
it would be interesting to clarify and/or analyze in future studies the possible effect of 
melatonin on glaucomatous TM cells.  
Several authors have demonstrated that SIRT1 may also prevent oxidative stress-induced 
TM DNA damage and retinal ganglion cell death as well as axonal degeneration.163,238-240 
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Consequently, melatonin treatment regulating SIRT1 expression/activity, could be a useful 
strategy to prevent these effects and thus, glaucoma progression (Fig. 2).113-115,117 
Additionally, and in experimental models of optic neuritis and retinal ischemia, melatonin 
treatment inhibits glial reactivity and reduces the expression of hypoxia inducible factor -1α, 
COX-2 and TNFα genes (Fig. 2).241,242 It is, thereby, also acting as a neuroprotective agent. 
In relation to these effects, Jiang and colleagues have demonstrated that melatonin 
decreases the production of VEGF by Müller cells, the main retinal glial cells, under high 
glucose concentration.243 Considering all these facts, the use of melatonin seems to be an 
appropriate strategy to prevent and treat glaucoma (Fig. 2). 
 
3.2.2 A new therapeutic consideration: melatonin and autophagy 
Since mitochondrial damage plays a critical role in glaucoma development, mitophagy and in 
general autophagy processes should also be important. Indeed, Coughlin and colleagues 
have detected a deficient mitophagy process in the optic nerve of glaucomatous mice.244 On 
the other hand, several authors have demonstrated that after optic nerve transection, 
elevation of IOP, ischemia or optic nerve crush, autophagy levels increase.245-249 
Nevertheless, the role of autophagy in glaucoma neurodegeneration is still unclear. Several 
studies have suggested that autophagy promotes the survival of retinal ganglion cells after 
oxidative injury.249-251 Conversely, other authors have suggested that autophagy promotes 
retinal ganglion cell death and axonal degeneration.245,246,248 Alternatively, Park and 
colleagues have proposed that autophagy is initially activated in the dendrites of retinal 
ganglion cells where it promotes neuroprotection and afterwards it is activated in the 
cytoplasm where it provokes cell death.247  
Other cells key in glaucoma occurrence and progression such as glial and trabecular 
meshwork cells also experiment changes in the autophagy processes. Consequently, Tezel 
and colleagues have reported the overexpression of autophagy-related proteins in astrocytes 
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of glaucomatous rats.252 Regarding TM, Pulliero and colleagues have demonstrated that 
aging promotes the autophagy processes in human TM.128 Additionally, some authors have 
demonstrated that porcine TM cells submitted to oxidative stress accumulate defective 
mitochondria as well as autophagic/lysosomal vacuoles and trigger autophagy 
induction.253,254 Nevertheless, since oxidative stress also impairs lysosomal activity and 
reduces lysosomal acidification, the autophagic flux is finally decreased.253,254 More recently, 
Porter and colleagues demonstrated a mTOR-dependent dysregulation of autophagy 
pathway in human glaucomatous TM cells.255 Melatonin can induce mTOR pathway and 
thereby play a role in this process (Fig. 2).256 Since alterations in TM autophagy may be 
critical for glaucoma onset and/or progression, it seems necessary to clarify this point. 
 
3.3. Age-related macular degeneration 
Macular diseases are the third most common cause of visual impairment (3.1 % of all visually 
impaired people) and blindness (6.6 % of all blind people) worldwide.257 Age-related macular 
degeneration (AMD) is a disease with a complex etiology including aging, genetic 
predisposition and environmental determinants (risk factors have been reviewed in258). The 
disease affects the macular region of the eye containing photoreceptors, retinal pigment 
epithelium (RPE), Bruch´s membrane and choriocapillaris.259 RPE protects photoreceptors 
against photo-oxidative stress by absorption of light radiation and phagocytosis of their outer 
segment membranes. Additionally, and since RPE participates in the visual cycle 
(biochemical reactions that regenerate photoreceptor visual pigment), controls ion 
homeostasis in the subretinal space and supplies nutrients to photoreceptors, it maintains 
photoreceptor´s functions.260 Consequently, RPE dysfunction is a primary event in 
photoreceptor degeneration and in AMD development.261,262  
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3.3.1 The therapeutic potential of melatonin in AMD: oxidative stress 
Aged photoreceptors, choriocapillaris and RPE cells are subjected to intense oxidative insult 
because of their constant exposure to visible light, daily phagocytosis of photoreceptor outer 
segments, high local oxygen concentrations, presence of intracellular photosensitizers and 
choroidal blood photoactive compounds.263-268 Additionally, RPE cells present inadequate 
systems of antioxidant defense and mitochondrial DNA repair.269-271 Consequently, these 
cells and specially RPE cells accumulate oxidative damage with age (mainly mitochondrial 
and DNA damage) that alters their bioenergetics status, thus compromising cell function and 
viability. Certainly, during aging and particularly in AMD, the number/area of mitochondria as 
well as the content of mitochondrial electron transport chain proteins in RPE cells, is 
diminishing.272,273 Furthermore, several authors have demonstrated that in AMD disease, 
RPE cells accumulate a high level of mitochondrial DNA damage, even more than in age-
matched cells.274-276  
Melatonin, as a potent antioxidant/mitochondrial protector, can counteract oxidative stress 
and increases viability of RPE cells as well as of photoreceptors (Fig. 2).277-280 This indole-
derived component scavenges free radicals but also regulates transcription of antioxidant 
genes via Nrf2 activation.32,37-44  
Rosen and colleagues have reported that nocturnal melatonin production is decreased in 
AMD patients when compared to age-matched controls.281 Consequently, and considering 
the melatonin antioxidant effects, its decreased synthesis can contribute to the oxidative 
insult and finally occurrence of AMD. In fact, aged RPE cells have impaired Nrf2 signaling 
making them especially vulnerable to oxidative damage.270,282 Furthermore, and since some 
authors point to oxidative stress and Nrf2- mediated antioxidant defense as promising targets 
to prevent or treat AMD, exogenous melatonin might also be useful for this purpose (Fig. 
2).270,276,282,283 Indeed, a preliminary study has demonstrated that the daily use of 3 mg of 
melatonin, during 3 months, protects the retina and delays macular degeneration.284 
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3.3.2 A new therapeutic consideration in AMD: melatonin and autophagy 
As previously mentioned, autophagy and its variants act as a second line of defense against 
oxidative damage.5 During aging, they degrade non-functional proteins or protein aggregates 
and damaged organelles.261 Therefore, the excessive accumulation of mitochondrial damage 
in AMD suggests a failure in these processes. Indeed, mitophagy – selective autophagy or 
degradation of mitochondria – diminishes in RPE cells in the early stages of AMD.285 
Phagocytosis of photoreceptor outer segments is another autophagy-related degradation 
system of RPE.261 This process guarantees viability of photoreceptors and thus, visual 
function.260,286,287 Scütt and colleagues have demonstrated that the impairing of mitochondrial 
activity diminishes the phagocytic and autophagic capacities of RPE cells.288 Consequently, 
aged RPE cells accumulate damaged organelles such as mitochondria as well as non-
functional or toxic proteins including the pigment lipofuscin.261,289 The excessive accumulation 
of this pigment may be harmful to RPE cells, since it is a toxic photosensitizer.290-292 In fact, 
many studies support the idea of a causal relationship between lipofuscin accumulation and 
AMD onset/progression.291,293,294 Photooxidation products of the bisretinoids – component of 
lipofuscin – and of DHA, activate complement system.294,295 Consequently, they may promote 
para-inflammation and drusen formation (extracellular deposits predominantly localized 
beneath RPE that impair its metabolic connection with choroid).258,294 Both, immuno-
inflammatory events (e.g. complement, inflammasome and microglial/macrophage activation) 
and drusogenesis (drusen formation, triggered by reduced autophagy and complement 
activation)130,296-299 play a reliable role in pathogenesis and progression of AMD (reviewed 
in130,258).  
It is well known that the phagocytic and autophagic processes of RPE cells are controlled by 
circadian rhythms.300-302 Some studies have demonstrated that melatonin, a key regulator of 
retinal circadian rhythms, regulates photoreceptor outer segment phagocytosis whereas 
others have not.303,304 More recently, Yao and colleagues have demonstrated a circadian and 
light-dependent modulation of autophagy in photoreceptors.302 Conversely, autophagy in 
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RPE cells is an independent-light process but occurs in response to photoreceptor 
phagocytosis.302 The possible involvement of melatonin in these processes is unknown. 
Since failure in autophagy is a critical event in AMD pathogenesis, it seems necessary to 
clarify this point (Fig. 2).  
In any case, retinal circadian clocks prevent melatonin secretion in the presence of light and 
thus protect photoreceptors against light-induced damage (Fig. 2).305-307 Additionally, 
melatonin induces melanosome (melanin granule) aggregation in RPE cells and therefore, 
protects them from light-induced apoptosis (Fig. 2).308,309 Indeed, RPE melanin pigment 
absorbs light and scavenges light-induced free radicals acting as an antioxidant agent.310 In 
the aging RPE, melanin experiments oxidative changes (it binds lipofuscin) and therefore, 
loses its photoprotective capacity.311 This fact confirms the protective role of melatonin and 
its potential to prevent/treat AMD disease (Fig. 2).  
As previously mentioned, ROS can also promote telomere erosion that contributes to cellular 
aging process.10-13 Indeed, Honda and colleagues demonstrated that RPE aged cells exhibit 
accelerated telomere shorting.312 Since melatonin can modulate telomerase activity and 
retina contains active telomerase, its age-related deficiency can also contribute to the RPE 
cell damage (Fig. 2).42,118,313 In fact, some authors have suggested that melatonin may be 
useful in preventing or treating AMD by its capacity to modulate telomerase.314,315  
 
3.3.3 A novel therapeutic consideration: melatonin and angiogenesis 
The more severe complication of AMD, choroidal neovascularization (the growth of new 
vessels derived of choriocapillaris into the subretinal space) is also triggered by ROS 
accumulation (principally mitochondrial ROS). ROS promotes the expression of pro-
angiogenic mediators and thereby, participates in retinal angiogenesis.316 Atienzar-Aroca and 
colleagues have demonstrated that RPE cells, under oxidative stress, release a large 
amount of vascular endothelial growth factor (VEGF) receptor-loaded exosomes capable of 
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promoting angiogenesis (this factor regulates retinal vascular leakage and proliferation). 317 
Furthermore, protein adducts formed by peroxidation of DHA and RPE lipofuscin induce 
angiogenesis by VEGF-independent pathways.293,318,319 Additionally, pro-angiogenic 
cytokines generated by lipofuscin promote accumulation of macrophages that may release 
new angiogenic promoters and then amplify the angiogenesis process.319,320 In fact, Wang 
and colleagues have recently suggested that the tumor necrosis factor alpha (TNF-α, pro-
inflammatory cytokine generated mainly by macrophages) induces the expression of VEGF 
in RPE cells, through a mechanism ROS-dependent, and thus mediates choroidal 
neovascularization.321 
Melatonin also protects against the breakdown of the retinal-blood-barrier (BRB) that occurs 
in retinal neovascularization (Fig. 2).322 Indeed, melatonin reduces the level of VEGF as well 
as NO in retina and thus, prevents BRB breakdown (Fig. 2).322 These facts once again 
confirm the role of melatonin in the occurrence of AMD and that the administration of 
melatonin might be beneficial in treating this disease. Indeed, anti-VEGF strategy is routinely 
used to treat choroidal neovascularization.323 Since the choroidal neovascularization 
response to anti-VEGF therapy is variable, its combination with anti-inflammatory agents is 
frequent.324,325 Consequently, a combination of antiangiogenic agents with melatonin (with 
antioxidant/mitochondrial protector, antiangiogenic, anti-inflammatory as well as 
immunomodulatory effect) could improve the efficacy of AMD therapy. 
 
3.4. Diabetic retinopathy 
According to a 2012 World Health Organization (WHO) report, diabetic retinopathy is 
responsible for 1 per cent of visual impairment and blindness worldwide.131 Diabetic 
retinopathy is the most common ocular complication derived from diabetes mellitus. Chronic 
hyperglycemia of diabetes, and to a lesser extent hyperlipidemia as well as hypertension, 
induce changes in the permeability of retinal blood vessels and reduce retinal oxygenation. 
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Therefore, abnormal new blood vessels grow and invade vitreous humor that can finally 
produce blindness (stage of the disease called proliferative diabetic retinopathy).326 Diabetes 
is an age-related disease (elderly adults present twice the prevalence compared to middle-
aged or young adults) and thus, oxidative stress plays a prominent role in its 
development.327,328 Furthermore, oxidative stress underlies the pathogenesis of diabetic 
retinopathy.328 In fact, diabetic retinopathy patients present higher levels of plasma lipid 
peroxidation than diabetes patients without diabetic retinopathy.328 Retinal enzymatic (e.g. 
cytosolic NADPH oxidase and arginase activation) and non-enzymatic (mainly via 
mitochondrial damage) mechanisms produce excessive ROS in diabetic retinopathy.329-331 
Additionally, auto-oxidation of glucose and metabolic abnormalities induced by 
hyperglycemia (e.g. activation of polyol as well as hexosamine pathways, protein kinase C 
activation and formation of advanced glycation endproducts - AGE) increase ROS production 
in diabetes (reviewed in332). Furthermore, inflammatory processes contribute to the 
development of diabetic retinopathy and so is considered a low grade chronic inflammatory 
disease.333 Indeed, inflammatory mediators including iNOS, COX-2, VEGF and NF-κB are 
up-regulated in this condition.333 NF-κB activation evokes cytokines release that can 
generate more ROS. Moreover, Romeo and colleagues suggested that the activation of NF-
κB triggers apoptosis in retinal capillary cells.334 Other sources of ROS and inflammation in 
diabetic retinopathy, are the photoreceptors.335  
 
3.4.1 The therapeutic potential of melatonin in diabetic retinopathy: nitro-oxidative 
stress 
The impairment of the antioxidant defense system and mitochondrial DNA repair machinery 
also contributes to the oxidative burden of retina. Certainly, mitochondrial manganese 
superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase are 
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decreased in diabetic retina.332,336 This effect is due, at least in part, to the fact that DNA-
binding activity of Nrf2 is also decreased.337  
Regarding DNA repair enzymes, both base excision repair as well as mismatch repair 
enzymes fail to repair damaged mitochondrial DNA and thus, its replication and transcription 
is impaired.338-340 Consequently, the mitochondrial function is compromised and finally 
triggers apoptosis of capillary cells.338-340  
Considering all these facts, the use of mitochondria-targeted antioxidants seems to be an 
appropriate strategy to treat diabetic retinopathy. In this context, melatonin acts as a 
mitochondria-targeted antioxidant and as a retinal cytoprotective agent (Fig. 2).56,277-280,341,342 
Certainly, melatonin offers protection from oxidative stress and increases the viability of 
retinal cells involved in diabetic retinopathy including RPE, photoreceptors, retinal ganglion 
cells and Müller cells (Fig. 2).243,277-280 Furthermore, melatonin prevents the nitro-oxidative 
stress of diabetic retina343-345 and high glucose-induced inflammatory response of RPE as 
well as retinal endothelial cells (Fig. 2).346 
In addition, melatonin may also play a role in the occurrence of diabetic retinopathy. In fact, 
do Carmo Buonfiglio and colleagues have reported that retinal melatonin synthesis and its 
content are reduced in diabetic rat retinas.347 Various authors have also demonstrated that 
melatonin secretion is diminished in patients with proliferative diabetic retinopathy.348,349 
Since melatonin acts as an antioxidant/mitochondrial protector as well as an inflammatory 
agent, its deficiency may contribute to the progression of diabetic retinopathy.  
 
3.4.2 New therapeutic possibility: melatonin and sirtuins 
Epigenetic modifications also contribute to the mitochondrial damage in diabetic retinopathy 
(Reviewed in332). Oxidative stress produces changes in the acetylation and methylation of 
histones present at the promoter of genes key in this disease (Reviewed in332). 
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Consequently, sirtuins play an important role in the occurrence/progression of diabetic 
retinopathy. In this context, Kowluru and colleagues have demonstrated that diabetes-
induced oxidative stress inhibits SIRT1 permitting NF-κB acetylation and thereby, the 
activation of matrix metalloproteinase-9 (MMP-9) transcription.330 MMP-9 protein triggers 
apoptosis in the early stages of disease and contributes to angiogenesis in a later phase.350 
Therefore, resveratrol - a stabilizer of SIRT1-substrate interaction - prevents extracellular 
glutamate accumulation in diabetic rat retinas through modulation of glutamate transporter 
GLAST and glutamine synthetase expression.154,351 This SIRT1-mediated effect permits the 
rescue of neuronal cells, which are affected in diabetic retinopathy, from death.351 Indeed, in 
diabetic retinopathy the glutamatergic system (glutamate receptors and transporters)352-354 
and synaptic function (exocytotic proteins)353 are impaired and contribute to excitotoxicity as 
well as neuronal degeneration. In this context, melatonin as a modulator of sirtuins and anti-
excitatory molecule, may be useful to prevent and treat diabetic retinopathy (Fig. 2).67,113-117  
On the other hand, overexpression of SIRT3 down-regulates pro-angiogenic mediators such 
as MMP-9 as well as VEGF and up-regulates the expression of autophagy-related genes.355  
 
3.4.2 New therapeutic considerations in diabetic retinopathy: melatonin, autophagy 
and angiogenesis 
Autophagy also plays an important role in the onset/progression of diabetic retinopathy, as 
commented. Shi and colleagues have demonstrated that inhibition of autophagy mediates 
the activation of NLRP3 inflammasome in RPE cells subjected to high glucose stress.356 
Rapamycin, an activator of autophagy, also diminishes VEGF expression as well as oxidative 
stress in diabetic retinas by blocking the kinase mTOR.357  
All these data suggest that autophagy modulation (e.g. via sirtuins or mTOR) may be a 
promising therapeutic target for prevention/treatment of proliferative diabetic retinopathy. In 
this sense, melatonin can modulate sirtuins expression/activity and can induce autophagy via 
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mTOR-dependent pathway (Fig. 2).113-117,256 Furthermore, some of the sirtuins effects 
described above, have also been reported for melatonin.243,344-346 Indeed, melatonin 
treatment of diabetic rats inhibits their MMP-9 expression and VEGF secretion (Fig. 2).344,345 
Jiang and colleagues have also demonstrated that high glucose-induced VEGF production of 
Müller cells, which are an important source of retinal VEGF, is reduced by melatonin 
treatment (Fig. 2).243 In humans, the treatment with melatonin also reduces the level of VEGF 
secreted by retinal endothelial and RPE cells subjected to high glucose concentration.346 
Since melatonin reduces the level of VEGF and NO in hypoxic as well as diabetic rat retinas, 
melatonin can also prevent BRB breakdown (Fig. 2).322,344,345 These facts, once again, 
confirm the role of melatonin in the occurrence of proliferative diabetic retinopathy, 
suggesting that administration of melatonin might be beneficial to prevent and treat this 
disease. 
 
4. EPILOGUE AND PERSPECTIVES 
In 2012, the proportion of world population aged 60 or over was 11.5 per cent and United 
Nations estimates that this percentage will double by 2050 (http://unfpa.org/ageingreport/). 
Consistent with this trend, scientific community expects a higher prevalence of age-related 
conditions including eye diseases.358,359 Additionally, the World Health Organization (WHO) 
estimated that the percentage of people visually impaired or blind among the older 
population for 2010, were 65 and 82 per cent, respectively.131 Therefore, the researchers are 
trying to develop effective interventions to maintain ocular health and reduce the burden of 
age-related eye diseases, including cataract, glaucoma, age-related macular degeneration 
and diabetic retinopathy. The aforementioned diseases, share underlying molecular 
processes of aging and other age-related diseases. This fact agrees with the study of 
Johnson and colleagues that demonstrates the influence of common anti-aging pathways in 
human age-related diseases 360. In fact, these ocular pathologies present the nitro-oxidative 
damage, mainly at mitochondrial level, as a major cause.124,125,178,179,262,328 Furthermore, 
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several authors have demonstrated that autophagy is impaired in cataract, glaucoma, age-
related macular degeneration and diabetic retinopathy diseases, suggesting that autophagy 
is a contributing factor to their evolution.128,163,250,261,356 This fact could be explained by the 
post-mitotic nature of the main cells involved in the mentioned ocular diseases, where 
autophagy plays a critical role in removing oxidized proteins or damaged mitochondria and 
restoring their cellular homeostasis.5,129 
Other conditions such as low grade chronic inflammation and angiogenesis also contribute to 
the development of age-related retinal diseases including glaucoma, age-related macular 
degeneration and diabetic retinopathy.130,209,361-364 
In this context, melatonin presents several direct and indirect (e.g. via Nrf2 or sirtuins 
modulation) actions including antioxidant/antinitridergic, mitochondrial protection, autophagy 
modulation, anti-inflammatory and anti-angiogenic, in ocular tissues. Consequently, this 
pleiotropic molecule can represent a powerful tool to prevent and counteract these complex 
age-related eye diseases. Indeed, some authors have demonstrated its beneficial effects, in 
human short- clinical studies, of age-related macular degeneration and glaucoma.217,284 
In addition to its pleiotropic actions, melatonin possesses an advantage over other possible 
candidates due to its amphiphilic character, which enables it to enter any fluid, cell or 
subcellular structures including mitochondria.56,57,365,366 Furthermore, Crooke and colleagues 
have demonstrated that the melatonin combination with classical anti-glaucoma drugs 
potentiates their effects on animals.226 Therefore, the combination of melatonin with other 
drugs could improve the efficacy of classical drugs in patients with the mentioned diseases. 
In fact, the combination therapy is a common strategy in glaucoma and age-related macular 
degeneration.367,368 Moreover, Rivara and colleagues, have reported that the current trend in 
melatonin invention disclosures is the co-administration of melatonin with other drugs to 
increase the efficacy of treatment and reduce side-effects.369 In this context, toxicological 
studies in humans have demonstrated the safe profile of melatonin, which is an important 
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requisite for drug combination (summarized in370). Conversely, melatonin exhibits poor 
pharmacokinetic properties (e.g. limited oral bioavailability and short plasma half-life) and low 
subtype receptor selectivity.371-376 For these reasons, researchers try to develop new 
melatonin analogues which are more metabolically stable, subtype-selective, and with 
melatonin beneficial properties.369,377 Despite the emerging role of melatonin in age-related 
ocular pathologies, the bulk of recent patent applications is directed towards sleep disorders 
and/or circadian rhythm-related illnesses.369 In this sense, a reduced number of melatonin 
analogues (MCA-NAT, IIK7, agomelatine, INS48848, INS48862 and INS48852) have been 
tested for their in vivo ocular hypotensive effect.213 Additionally, researchers have 
demonstrated the neuroprotective action of agomelatine, which is a melatonin analogue 
approved to treat depression.378 Consequently, it is also necessary to characterize in a more 
detailed way all the properties of these melatonin analogues to determine their efficacy to 
treat ocular diseases. 
Considering all these factors, we can conclude that melatonin, as a single agent or in 
combination with other drugs, is an attractive pharmacological candidate for cataract, 
glaucoma, age-related macular degeneration and diabetic retinopathy. Further experimental 
evidences are needed to support the usefulness of melatonin analogues in these ocular age-
related diseases. 
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FIGURES AND TABLES 
FIGURE 1. Schematic depiction of the multiple intracellular actions of melatonin 
involved in cellular aging processes. Green and red arrows indicate positive and negative 
interactions, respectively, between two consecutive steps. Dashed arrow indicates 
interaction not elucidated. MT1/MT2, melatonin membrane receptors; MT3, putative melatonin 
receptor; IR/IGFR, insulin/insulin-like growth factor 1 receptor; AC, Adenylate cyclase; PLC, 
phospholipase C; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, protein 
kinase C; AKT, protein kinase B; ERK, extracellular signal-regulated kinase; JNK, c-Jun 
amino-terminal kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
Nrf2, nuclear factor erythroid 2‐related factor 2; FoxO, forkhead box-O transcription factor; 
CREB, cAMP response element-binding. The signaling pathways information has been 
compiled from: 18,32,53,86,379,380. 
 
FIGURE 2. Overview of the confirmed and suggested actions of melatonin in age-
related ocular diseases.  
TABLE 1. Anti-aging effects of melatonin and its mediators. 
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TABLE 1. Anti-aging effects of melatonin and its mediators. 
 
 
Melatonin function Possible mediators References Mediators function References 
Regulator of 
physiological circadian 
rhythm processes 
Sirtuins: melatonin induces SIRT1 
expression in SAMP8 mice, in sleep-
deprived rats and in neuronal cultures 
of aged rats. 
113,114,117
 
SIRT1 negatively regulates 
CLOCK/BMAL1-complex. 
111
 
SIRT3 acetylates and actives 
oxidative enzymes and respiration 
in isolated mitochondria. Thereby, it 
regulates rhythmicity of 
mitochondrial respiration. 
111,112
 
Antioxidant/protector 
of mitochondria 
function 
Antioxidant enzymes (superoxide 
dismutase, catalase and glutathione 
peroxidase): melatonin increases the 
expression and activity of antioxidant 
enzymes under oxidative stress 
conditions and in the liver of aging rats.  
Melatonin enhances antioxidant 
enzyme gene expression via Nrf2 
activation. 
47,50,52
 
Antioxidant enzymes removal free 
radicals such as superoxide anion 
and hydrogen as well as lipid 
peroxides. 
 
380
 
 
Nitric oxide synthases (NOS): 
melatonin and its metabolite AMK 
inhibit nNOS, iNOS and i-mtNOS 
enzymes. These effects have been 
tested in murine macrophages 
stimulated with endotoxin, in 
parkinsonian mice and in a rat model of 
dimethylnitrosamine-induced liver 
injury. 
Melatonin inhibits iNOS gene 
expression via NF-κB inactivation. 
31,33,45-
47,49
 
NOS enzymes catalyze the 
synthesis of NO, a molecule that 
regulates respiratory chain, 
generation of free radicals and 
mitochondrial apoptosis. 
55
 
 
Insulin/IGF-1 signaling (IIS) pathways: 
melatonin induces phosphorylation of 
insulin/IGF-1 receptors and modulates 
PI3K/AKT and ERK/MAPK pathways. 
These effects have been demonstrated 
in isolated pancreatic islets of neonate 
and adult rats as well as in an insulin-
secreting cell line. 
37,86
  
IIS pathways regulate mitochondrial 
biogenesis and function. PI3K/AKT 
pathway control the expression of 
genes involved in stress resistance 
and glucose as well as lipid 
metabolism. PI3K/AKT pathway can 
also modulate autophagy. 
IIS can also activate indirectly 
SIRT1 through its control of 
mitochondrial NAD+ level. 
82,84,90,381
 
Sirtuins: melatonin induces SIRT1 
expression in SAMP8 mice, in sleep-
33,113,114
 
SIRT1 reduces apoptosis in the 
presence of stress stimuli. 
93
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deprived rats and in neuronal cultures 
of aged rats. SIRT1 increases the expression levels of antioxidant enzymes such 
as superoxide dismutase and 
catalase. 
102-104
  
SIRT1 induces mitochondrial 
biogenesis by upregulation of 
endothelial NOS. 
105
 
SIRT1 modulate autophagy 
process. 
81,106
 
SIRT1 regulates the expression of 
IGF-1 and its receptor as well as the 
activity of FoxO transcription factor 
that is a downstream target of IIS 
pathway. Furthermore, it protects 
pancreatic beta cells, modulates 
insulin secretion and improve insulin 
sensitivity under insulin-resistant 
conditions. 
93,94,97,99-
101
 
Anti-inflammatory Cyclooxygenase-2 (COX-2): melatonin 
and its metabolites prevent specifically 
the activation of COX-2 in murine 
macrophages activated with endotoxin. 
Furthermore, melatonin suppresses 
NF-κB binding to DNA and therefore 
decreases the levels of macrophage 
COX-2 transcript. 
32,45
 
COX-2 enzyme regulates 
prostaglandins production that is 
key in the initiation of inflammatory 
process. 
382
 
 
Glutamatergic system: melatonin 
increases glutamate clearance and its 
conversion to glutamine in golden 
hamster retina. Additionally, it inhibits 
N-methyl-D-aspartate and kainate 
receptors activation in rats. 
67,68,71
 
High levels of glutamate around the 
synaptic cleft cause excitotoxicity. 
 
 
383,384
 
 
Nitric oxide synthases (NOS): 
melatonin and its metabolite AMK 
inhibit nNOS, iNOS and i-mtNOS 
enzymes. These effects have been 
tested in murine macrophages 
stimulated with endotoxin, in 
parkinsonian mice and in a rat model of 
dimethylnitrosamine-induced liver injury 
Melatonin inhibits iNOS gene 
expression via NF-κB inactivation. 
31,33,45-49
 
In the presence of high levels of 
glutamate, NO synthesis may be 
excessive and thereby NO may 
become neurotoxic. 
54,65
 
NO is also an immune modulator. 74
 
 
GABAergic and glycinergic systems: 
melatonin enhances these systems. 
66,69,72,73
 
Possible compensation of over-
excitation by enhancing inhibitory 
385
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synaptic transmission. 
 
Sirtuins: melatonin induces SIRT1 
expression in SAMP8 mice, in sleep-
deprived rats and in neuronal cultures 
of aged rats. 
113,114,117
 
SIRT1 inhibits NF-kB transcription 
factor and thereby it can abolish 
inflammatory response. 
16,18,95,107,
108
 
Telomere attrition Sirtuins: melatonin induces SIRT1 
expression in SAMP8 mice, in sleep-
deprived rats and in neuronal cultures 
of aged rats. 
113,114,117
 
SIRT1 maintains telomere stability. 109,110
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